SCHEMBL5166757

SCHEMBL5166757

COC(=O)C=[N+]([O-])CCc1cccc(I)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.44
CYP4F2 P78329 3/20 0.37
CYP4A11 Q02928 3/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HSP90AA1 P07900 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NLRP1 Q9C000 1/20 0.36
IDO1 P14902 2/20 0.36
FAAH O00519 1/20 0.34
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12530396 0.89 TRPV1 (0.40) TRPV1MEN1ALDH1A1HSP90AA1MAPT
SCHEMBL15012993 0.77 TRPV1 (0.38) TRPV1MEN1ALDH1A1HSP90AA1MAPT
SCHEMBL13006758 0.73 MEN1 (0.55) MEN1ALDH1A1HSP90AA1MAPTHPGD
SCHEMBL13005771 0.72 CYP1A2 (0.38) TRPV1IDO1FAAHCYP1A2CYP2D6
SCHEMBL6045414 0.72 CYP1A2 (0.38) TRPV1IDO1FAAHCYP1A2CYP2D6
SCHEMBL6045415 0.72 CYP1A2 (0.38) TRPV1IDO1FAAHCYP1A2CYP2D6
SCHEMBL972580 0.71 SIRT2 (0.51) TRPV1CYP4F2CYP4A11ALDH1A1IDO1
SCHEMBL13006100 0.69 SLC6A3 (0.39) TRPV1MEN1ALDH1A1HSP90AA1MAPT
SCHEMBL133271 0.69 SLC6A3 (0.39) TRPV1MEN1ALDH1A1HSP90AA1MAPT
SCHEMBL7173394 0.69 ALDH1A1 (0.47) TRPV1CYP4F2CYP4A11ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1768966-A1 COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS Infinity Pharmaceuticals, Inc. (US) 2007-04-04 EP disclosed
WO-2006009869-A1 COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS INFINITY PHARMACEUTICALS, INC. (US) 2006-01-26 WO disclosed